Galectin Therapeutics Inc (NASDAQ:GALT) is crash-landing 35% to the market floor once investors caught word of the biotech firm’s Phase 2b NASH-CX study …
Neuralstem (NASDAQ:CUR) stock is on fire after revealing a huge clinical win that has sent bulls storming the market today to buy into …
Is Billionaire fund guru Jim Simons switching OPK for VRX?
Canaccord’s John Newman sees 24% upside potential for BLUE shares.
BTIG’s Tim Chiang still spots challenges in VRX’s orbit, but likewise pinpoints strength in eyecare business Bausch + Lomb, which boasts robust international gains.
Now that ADMP has submitted a PAS for its pediatric version of Symjepi, an epipnephrine injection cheaper than Mylan’s EpiPen, FBR’s Andrew D’silva sees a potential approval with less risk than the original version.
Maxim’s McCarthy now sees 27% upside potential for Gilead, impressed with management’s plans for lymphoma asset Yescarta.
Cantor’s William Tanner smirks as bears run low on “ammunition” to doubt TXMD on the heels of news of an NDA resubmission to the FDA for TX-004.
Ken Griffin is a man known to be raring to take a risk when it is worthwhile, a daring and strategic mindset that …
Mizuho’s Irina Rivkind Koffler may remain apprehensive on generics competition, but the analyst likes what she sees with new plans for corporate restructuring.
